azetukalner — Topline data
H1 2027
• Three Phase 3 studies of azetukalner in neuropsychiatry continue to advance, with topline data from X-NOVA2 study in MDD expected H1 2027Source filing
XENE biotech catalysts & pipeline
XENON PHARMACEUTICALS INC · Data as of 2026-10-25
Upcoming catalysts
NBI-921355 — Initial data
2027
Data from the Phase 1b study are expected in 2027.Source filing